Spinal Muscular Atrophy Treatment Market

During the forecast period, the spinal muscular atrophy treatment market will exhibit dynamic growth.

The global spinal muscular atrophy treatment market is growing proficiently and is expected to grow at a CAGR of 14.5%. Globally, the increasing incidence of SMA, along with improved treatment management through innovative gene therapy and drugs, will drive the growth of the market. Increasing awareness, FDA approval for new drugs, partnerships for enhanced R&D, and private funding will boost the overall demand for SMA treatment on a global scale.

Market Synopsis

Type I SMA treatment to witness a significant CAGR.

Growing hospital admissions for type I SMA and its therapeutic reatment generated the largest revenue share in 2018. Increasing incidences of SMA in infants and advancements in gene therapy, along with strong pipeline drugs internationally, will drive the market’s growth. New drug development for type II and III will show promising growth in the near future. Enhanced joint development programs for innovative therapies will drive the demand in the near future, such as Risdiplam (RG7916), reldesemtiv (CK-2127107), Branaplam (LMI070), and others.

Gene therapy treatment is expected to witness a significant CAGR in the near future.

Drugs accounted for the maximum revenue share in 2018. In 2018, drugs emerged as the principal treatment application for spinal muscular atrophy (SMA) since Spinraza (developed by Biogen and Ionis Pharmaceuticals) is the only drug approved to date. Additionally, in May 2019, the U.S. FDA approved Zolgensma® (onasemnogene abeparvovec-xiii) by AveXis (Novartis AG), the first gene therapy for infants (less than two years of age) suffering from spinal muscular atrophy.

Advancements in gene therapy, FDA approval of new drugs, and strong pipeline products offer a huge advantage in the global SMA treatment market. If PTC Therapeutics and F. Hoffmann-La Roche AG proceeded with official plans to file for approval in the U.S. market and Europe by the end of 2019, it would set a possible approval date for the SMA treatment in the first half of 2020.

Increased research and development with strong product pipelines in the developed regions

Major players in the spinal muscular atrophy treatment market are Biogen Idec, Pfizer Inc., Boehringer Ingelheim, Isis Pharmaceuticals, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, AveXis Inc., Novartis AG, and others.

Mergers and acquisitions, partnerships, and improved R&D on targeted treatments for spinal muscular atrophy will further drive the overall market’s growth in the near future. Strong pipeline drugs will enhance the overall treatment management for SMA, such as Zolgensma (Novartis), Branaplam (Novartis), Amifampridine Phosphate (Catalyst Pharmaceuticals), Risdiplam (Hoffmann-La Roche), and others.

Historical and Forecast Period

This study report includes an analysis of each segment from 2017 to 2027, with 2018 as the base year. The compound annual growth rate (CAGR) for each of the respective segments is estimated for the forecast period from 2019 to 2027.

Report Scope by Segments

Market Segmentation

The current report also encompasses qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities that give a better understanding of the overall spinal muscular atrophy treatment market. Additionally, the global report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolios, and business strengths.

Key questions are answered in this report.

• What are the current market trends and dynamics in the spinal muscular atrophy treatment market, and what are the valuable opportunities for emerging players?
• Which segment accounts for the fastest CAGR during the forecast period?
• Which type of segment holds a larger market share and why?
• Are low- and middle-income economies investing in the spinal muscular atrophy treatment market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and the Middle East and Africa?

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Spinal Muscular Atrophy (SMA) Treatment Market
2.2. Global SMAT Market, by Type, 2018 (US$ Mn)
2.3. Global SMAT Market, Application, 2018 (US$ Mn)
2.4. Global SMAT Market, by Geography, 2018 (US$ Mn)

3. Market Dynamics
3.1. Introduction
3.1.1. Global SMAT Market Value, 2017-2027, (US$ Mn)
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.3. Attractive Investment Proposition, by Geography, 2018
3.4. Market Positioning of Key Players, 2018
3.4.1. Major Strategies Adopted by Key Players

4. Global Spinal Muscular Atrophy Treatment (SMAT) Market, by Type , 2017-2027 (US$ Mn)
4.1. Overview
4.2. Type I Spinal Muscular Atrophy
4.3. Type II Spinal Muscular Atrophy
4.4. Type III Spinal Muscular Atrophy

5. Global Spinal Muscular Atrophy Treatment (SMAT) Market, by Application, 2017-2027 (US$ Mn)
5.1. Gene Therapy
5.2. Drugs

6. North America Spinal Muscular Atrophy Treatment (SMAT) Market Analysis, 2017-2027 (US$ Mn)
6.1. Overview
6.1.1. North America SMAT Market Value and Growth, 2017-2027, (US$ Mn)
6.2. North America SMAT Market Value, By Type, 2017-2027 (US$ Mn)
6.2.1. Market Analysis
6.3. North America SMAT Market Value, Application, 2017-2027 (US$ Mn)
6.3.1. Market Analysis
6.4. North America SMAT Market Value, By Region/Country, 2017-2027 (US$ Mn)
6.4.1. Market Analysis
6.4.2. U.S.
6.4.3. Rest of North America

7. Europe Spinal Muscular Atrophy Treatment (SMAT) Market Analysis, 2017-2027 (US$ Mn)
7.1. Overview
7.1.1. Europe SMAT Market Value and Growth, 2017-2027, (US$ Mn)
7.2. Europe SMAT Market Value, By Type, 2017-2027 (US$ Mn)
7.2.1. Market Analysis
7.3. Europe SMAT Market Value, Application, 2017-2027 (US$ Mn)
7.3.1. Market Analysis
7.4. Europe SMAT Market Value, By Region/Country, 2017-2027 (US$ Mn)
7.4.1. Market Analysis
7.4.2. U.K.
7.4.3. Germany
7.4.4. France
7.4.5. Rest of Europe

8. Asia Pacific Spinal Muscular Atrophy Treatment (SMAT) Market Analysis, 2017-2027 (US$ Mn)
8.1. Overview
8.1.1. Asia Pacific SMAT Market Value and Growth, 2017-2027, (US$ Mn)
8.2. Asia Pacific SMAT Market Value, By Type, 2017-2027 (US$ Mn)
8.2.1. Market Analysis
8.3. Asia Pacific SMAT Market Value, Application, 2017-2027 (US$ Mn)
8.3.1. Market Analysis
8.4. Asia Pacific SMAT Market Value, By Region/Country, 2017-2027 (US$ Mn)
8.4.1. Market Analysis
8.4.2. Japan
8.4.3. China
8.4.4. India
8.4.5. Rest of Asia Pacific

9. Rest of the World Spinal Muscular Atrophy Treatment (SMAT) Market Analysis, 2017-2027 (US$ Mn)
9.1. Overview
9.1.1. Rest of the World SMAT Market Value and Growth, 2017-2027, (US$ Mn)
9.2. Rest of the World SMAT Market Value, By Type, 2017-2027 (US$ Mn)
9.2.1. Market Analysis
9.3. Rest of the World SMAT Market Value, Application, 2017-2027 (US$ Mn)
9.3.1. Market Analysis
9.4. Rest of the World SMAT Market Value, By Region, 2017-2027 (US$ Mn)
9.4.1. Market Analysis
9.4.2. Middle East & Africa
9.4.3. Latin America

10. Company Profiles
10.1. Biogen Idec.
10.2. Pfizer Inc.
10.3. Boehringer Ingelheim
10.4. Isis Pharmaceuticals
10.5. F. Hoffmann-La Roche
10.6. Regeneron Pharmaceuticals
10.7. AveXis Inc.
10.8. Novartis AG

List of Figures

FIG. 1 Global Spinal Muscular Atrophy Treatment (SMAT) Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global SMAT Market Segmentation
FIG. 4 Global SMAT Market, by Type, 2018 (US$ Mn)
FIG. 5 Global SMAT Market, by Application, 2018 (US$ Mn)
FIG. 6 Global SMAT Market, by Geography, 2018 (US$ Mn)
FIG. 7 Attractive Investment Proposition, by Geography, 2018
FIG. 8 Global Market Positioning of Key SMAT Market Manufacturers, 2018
FIG. 9 Global SMAT Market Value Share, by Type, 2018 & 2027 (Value %)
FIG. 10 Global Type I SMA Market, 2017–2027 (US$ Mn)
FIG. 11 Global Type II SMA Market, 2017–2027 (US$ Mn)
FIG. 12 Global Type II SMA Market, 2017–2027 (US$ Mn)
FIG. 13 Global SMAT Market Value Share, by Application, 2018 & 2027 (Value %)
FIG. 14 Global GeneTherapy Market For SMA, 2017–2027 (US$ Mn)
FIG. 15 Global Drugs Market For SMA, 2017–2027 (US$ Mn)
FIG. 16 North America SMAT Market, 2017–2027 (US$ Mn)
FIG. 17 Europe SMAT Market, 2017–2027 (US$ Mn)
FIG. 18 Asia Pacific SMAT Market, 2017–2027 (US$ Mn)
FIG. 19 RoW SMAT Market, 2017–2027 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Spinal Muscular Atrophy Treatment (SMAT) Market
TABLE 2 Impact Indicators
TABLE 3 Impact Analysis of Drivers and Restraints
TABLE 4 Global SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 5 Global SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 6 Global SMAT Market, by Geography, 2017–2027 (US$ Mn)
TABLE 7 North America SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 8 North America SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 9 North America SMAT Market, by Country, 2017–2027 (US$ Mn)
TABLE 10 Europe SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 11 Europe SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 12 Europe SMAT Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 13 Asia Pacific SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 14 Asia Pacific SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 15 Asia Pacific SMAT Market, by Country/Region, 2017–2027 (US$ Mn)
TABLE 16 Rest of the World SMAT Market, by Type, 2017–2027 (US$ Mn)
TABLE 17 Rest of the World SMAT Market, by Application, 2017–2027 (US$ Mn)
TABLE 18 Rest of the World SMAT Market, by Region, 2017–2027 (US$ Mn)
TABLE 19 Biogen Idec.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 20 Pfizer Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 21 Boehringer Ingelheim: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 22 Isis Pharmaceuticals: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 23 F. Hoffmann-La Roche: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 24 Regeneron Pharmaceuticals: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 25 AveXis Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 26 Novartis AG: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)